Drug Trial Radar · NCT05321147
Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2
Last checked: Nov 19, 2026Latest source record: Mar 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Mar 17, 2022
Primary completion
Nov 19, 2023
Study completion Feb 8, 2024
Sponsor
- Lead sponsor
- Innate PharmaIndustry
- Sponsor type
- Industry
- First posted
- Apr 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center phase Ib study, which evaluates the safety and efficacy of lacutamab monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2.
Conditions
- Peripheral T Cell Lymphoma
Interventions
lacutamabBiological
Patients will receive a fixed dose of 750mg as 1-hour IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of adverse events (AEs)Time frame: From consent is obtained until EOT visit (28 days after the last administration of study drug lacutamab)
Locations
20 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham- O'Neal Comprehensive Cancer Center
Birmingham, Alabama
University of California at Irvine - Chao Family Comprehensive Cancer Center
Orange, California
Goshen Health- Goshen Hospital
Goshen, Indiana
Indiana University School of Medicine
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
University of Maryland
Baltimore, Maryland
Memorial Sloan Kettering Cancer Center- David H. Koch Center for Cancer Care
New York, New York
Allegheny Health
Pittsburgh, Pennsylvania
Medical University of South Carolina - Health Hollings Cancer Center
Charleston, South Carolina
The University of Texas MD Anderson Cancer Center
Houston, Texas
Inje University Busan Paik Hospital
Busan, South Korea
Chungnam National University Hospital
Daejeon, South Korea
Seoul National University Bundang Hospital
Gyeonggi-do, South Korea
Gachon University Gil Medical Center
Incheon, South Korea
The Catholic University of Korea, Yeouido St. Mary's Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Korea University Anam Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital Yonsei University Health System
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.